One in three diabetic patients had primary headache in Qassim screening study
A cross-sectional study from two primary healthcare centers in Saudi Arabia’s Qassim region found that primary headache was common among adults living with diabetes mellitus, affecting 36.4% of the 313 enrolled patients. The finding places headache squarely inside routine diabetes care, where symptom review often centers on neuropathy, vision change, or glycemic control but can overlook recurrent head pain as a separate burden. In a condition defined by long-term metabolic stress, headache may be more than a nuisance complaint; it can be a marker of poor control, sleep disruption, vascular reactivity, or medication complexity.
The cohort was assembled by systematic sampling and included patients with type 1 and type 2 diabetes. Direct interviews and medical record review supplied the clinical and sociodemographic data, while a headache assessment questionnaire was used to classify symptoms. Median age was 60 years, and the median diabetes duration was 6 years. Women outnumbered men in the sample, with 183 female and 130 male participants, and the response rate reached 94.7%. Those baseline characteristics matter because headache epidemiology often shifts with age, sex, and chronic disease burden, especially in primary care populations where multiple complaints coexist.
Glycemic control and type 2 diabetes carried the strongest signal
The sharpest association emerged around metabolic control. Higher HbA1c levels were independently associated with primary headache, with an adjusted odds ratio of 1.26 and a 95% confidence interval of 1.06 to 1.48. In practical terms, worsening glycemia tracked with higher odds of headache in this diabetic population. The biological logic is plausible: chronic hyperglycemia can amplify inflammatory signaling, endothelial dysfunction, and small-vessel stress, all of which may lower the threshold for headache generation in vulnerable patients.
Type 2 diabetes also stood out. Compared with other diabetes categories in the analysis, T2DM was associated with a more than threefold higher odds of primary headache, with an adjusted odds ratio of 3.13 and a 95% confidence interval of 1.74 to 5.62. That difference is difficult to ignore in a primary care clinic where type 2 diabetes dominates the caseload. It also suggests that the metabolic and vascular milieu accompanying type 2 disease may be more relevant to headache burden than diabetes label alone.
Higher education and hemoglobin indices showed inverse associations
Not every signal pointed toward greater headache risk. Mean corpuscular hemoglobin concentration showed an inverse association with primary headache, with an adjusted odds ratio of 0.80 and a 95% confidence interval of 0.65 to 0.98. The study did not establish a mechanistic pathway, but hematologic indices can reflect broader physiologic states, including nutritional status, red cell characteristics, and chronic disease effects. In a population already managing diabetes, even modest shifts in blood indices may correlate with symptoms that are otherwise easy to miss during a standard follow-up visit.
Education also mattered in the opposite direction. A high educational level was associated with lower odds of primary headache, with an adjusted odds ratio of 0.47 and a 95% confidence interval of 0.22 to 0.98. That pattern can reflect several realities at once: better health literacy, earlier symptom recognition, more consistent diabetes self-management, and greater access to structured care. None of those explanations can be proven from a cross-sectional design, but each fits the clinical pattern of symptom burden clustering where disease control is less stable.
Why headache should be part of routine diabetes follow-up
This study’s practical message is straightforward. Headache affects a substantial share of diabetic patients, and its frequency rises where glycemic control is worse. In a routine diabetes visit, asking about recurrent headache may identify an additional source of disability, missed work, sleep disturbance, or unnecessary analgesic use. For a patient with poorly controlled diabetes, the symptom may be dismissed as incidental; the data argue for treating it as part of the broader metabolic assessment.
The study also sharpens the case for bedside vigilance in type 2 diabetes. Because type 2 disease often coexists with obesity, hypertension, dyslipidemia, and sleep problems, headache may emerge from overlapping pathways rather than a single cause. Hyperglycemia can irritate the vascular system, while chronic disease burden can increase stress and impair sleep quality, both of which can intensify primary headache disorders. Those mechanisms are clinically credible even if the study was designed to identify association rather than prove causation.
One in three patients had headache.
Limits of a cross-sectional design leave causality unresolved
The evidence stops short of showing whether poor glycemic control triggers headache, whether headache makes diabetes self-management harder, or whether both arise from a shared burden of comorbidity. Cross-sectional sampling can identify associations, but it cannot separate cause from consequence. The work was also drawn from two primary healthcare centers in one Saudi region, so the findings should be read as locally grounded rather than universally representative.
Still, the sample was sizable enough to show a clinically relevant signal, and the analysis adjusted for multiple factors. For frontline clinicians, the result is less about diagnosing a new disease and more about widening the symptom checklist. In diabetic care, headache deserves a place beside neuropathic pain, visual change, and foot symptoms, especially when HbA1c is elevated or when a patient carries type 2 diabetes and reports recurrent head pain during routine review.